Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed, metastatic or locally-, advanced pancreatic adenocarcinoma not amenable to curative resection.
Adequate renal, hepatic and bone marrow function.
Performance status 0 or 1.
You may not be if
Prior treatment with any systemic chemotherapy for metastatic disease.
Prior treatment with gemcitabine, AG-013736, or other vascular endothelial growth factor inhibitors.
Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent.
Inability to take oral medication.
Clareo Health | Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
